{"groups":[{"description":"Melphalan Lenalidomide Dexamethasone\n\ndexamethasone: 40 mg once weekly\n\nlenalidomide: 10 mg/day Days 1-21\n\nmelphalan: 5 mg/m2 Days 1-4","id":"FG000","title":"Melphalan Revlimid and Dexamethasone"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"7"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"inability to swallow oral drugs"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"16"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"12"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}